Pre-made Radretumab benchmark antibody ( di-scFv + CH4, anti-FN extra domain B therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Radretumab biosimilar, di-scFv + CH4: Anti-FN extra domain B therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-464-1mg	1mg	Inquiry
GMP-Bios-ab-464-10mg	10mg	Inquiry
GMP-Bios-ab-464-100mg	100mg	Inquiry
GMP-Bios-ab-464-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Radretumab biosimilar, di-scFv + CH4: Anti-FN extra domain B therapeutic antibody
INN Name	Radretumab
Target	FN extra domain B
Format	di-scFv + CH4
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgE
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	Philogen
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Brain cancer;Non-small cell lung cancer;Solid tumours;Haematological malignancies;Hodgkin's disease
Development Tech	na